Niraparib Efficacy in Patient With Unresectable Mesothelioma
Status:
Not yet recruiting
Trial end date:
2024-07-13
Target enrollment:
Participant gender:
Summary
Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of
niraparib versus active symptom control (ASC) in patients who have relapsed after previously
receiving platinum based systemic therapy. 84 patients will be recruited from approximately
10 UK trial network sites.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust